CXCR1 and neoplasm: Another compound being tested is ladarixin/DF2156A [73,74,75], a non-competitive allosteric inhibitor of CXCR1 and CXCR2 receptors, which has demonstrated anti-tumor properties for melanoma [75] and PDAC [76].